Guidance

Doxycycline as post-exposure prophylaxis for STIs: PHE response

Joint PHE and BASHH position statement on doxycycline post-exposure prophylaxis (PEP) for sexually transmitted infections (STIs).

Documents

Position statement on doxycycline as post-exposure prophylaxis (PEP) for STIs

Details

In this joint statement, Public Health England (PHE) and the British Association for Sexual Health and HIV (BASHH) do not endorse the use of Doxycycline PEP for STIs because any potential benefits will be outweighed by the considerable potential for antibiotic resistance to develop in STIs and other bacteria.

Further studies are required to measure the wider impact of prophylactic doxycycline on antibiotic resistance (AMR).

Updates to this page

Published 3 November 2017

Sign up for emails or print this page